丁型肝炎病毒基因5型与良好疾病结局及更佳治疗应答相关
结果显示基因5型患者较少发展为肝硬化或肝失代偿,且聚乙二醇干扰素治疗后应答率显著优于基因1型(64% vs 10%,p=0.013)。
要点
- HDV基因5型较基因1型肝硬化及肝失代偿发生率更低。
- 聚乙二醇干扰素治疗后应答率基因5型为64%,基因1型为10%(p=0.013)。
- 活跃复制HDV患者较暴露者更易发生肝脏并发症(p=0.002)。
核心结论
- 感染HDV基因5型的患者预后优于基因1型,肝失代偿更少且对聚乙二醇干扰素治疗应答更好。
主要发现
- 活跃复制HDV患者较HDV暴露患者更常发生肝脏并发症(p=0.002)。
- HDV基因5型患者较基因1型更少发展为肝硬化或肝失代偿。
关键数值与推荐
- 治疗后应答率:基因1型10%,基因5型64%(p=0.013)。
- 活跃复制HDV与肝脏并发症风险相关(p=0.002)。
临床怎么用
- 对HBV/HDV合并感染者应检测HDV基因型以评估预后和治疗应答。
- 基因5型患者可能需较少监测肝失代偿,但仍需个体化随访。
局限性
- 排除了随访短于6个月、合并HCV/HIV或急性HDV感染者,结论外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Coinfection with HDV causes rapid progression to liver cirrhosis and hepatic decompensation in patients with chronic hepatitis B. Factors that are associated with disease progression are poorly understood. In this study we aim to identify risk factors associated with disease progression and better characterise clinical differences and treatment response between HDV genotype 1 and 5. METHODS: In this retrospective study, all patients under our care between 2005 and 2016 with HBV/HDV coinfection (HBsAg+, anti-HDV antibodies positive) were analysed. Patients were excluded if follow-up was less than 6 months, if they had HCV and/or HIV coinfection or an acute HDV infection. Demographic data, stage of liver disease, development of liver complications and treatment response were recorded. RESULTS: One-hundred seven patients (mean age 36.0 years, 57% male) were followed for a median period of 4.4 years (range 0.6-28.1 years); 64% were of African origin and 17% were of European origin, with 28% of patients being cirrhotic at first visit; 43% patients had actively replicating HDV virus (anti-HDV-IgG+, anti-HDV-IgM+ or HDV RNA+) and 57% of patients were HDV exposed (anti-HDV-IgG+, HDV RNA-). Patients with actively replicating HDV more often developed liver complications than HDV-exposed patients (p = 0.002), but no differences in baseline characteristics were observed. Patients with HDV genotype 5 less often developed cirrhosis or hepatic decompensation compared to patients with HDV genotype 1. Twenty-four patients were treated with peg-IFN and post-treatment response was significantly better in patients infected with genotype 5 (10% GT1 vs. 64% GT5, p = 0.013). CONCLUSION: Patients infected with HDV genotype 5 appear to have a better prognosis with fewer episodes of hepatic decompensation and better response to peg-IFN treatment than patients infected with HDV genotype 1. LAY SUMMARY: Hepatitis delta is a virus that affects the liver. The virus is known to have different subtypes, called genotypes. With this research we discovered that hepatitis delta virus genotype 1 behaves differently than genotype 5 and causes faster development of liver disease. This is important for education of our patients and to determine how often we need to check our patients.
引用
- Spaan M, Carey I, Bruce M, et al. Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1. J Hepatol. 2020. PMID: 31981726. doi:10.1016/j.jhep.2019.12.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。